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Abstract
Background: Pontocerebellar hypoplasia (PCH) describes a rare, heterogeneous group of neurodegenerative
disorders mainly with a prenatal onset. Patients have severe hypoplasia or atrophy of cerebellum and pons, with
variable involvement of supratentorial structures, motor and cognitive impairments. Based on distinct clinical
features and genetic causes, current classification comprises 11 types of PCH.
Main text: In this review we describe the clinical, neuroradiological and genetic characteristics of the different
PCH subtypes, summarize the differential diagnosis and reflect on potential disease mechanisms in PCH.
Seventeen PCH-related genes are now listed in the OMIM database, most of them have a function in RNA
processing or translation. It is unknown why defects in these apparently ubiquitous processes result in a
brain-specific phenotype.
Conclusions: Many new PCH related genes and phenotypes have been described due to the appliance of next
generation sequencing techniques. By including such a broad range of phenotypes, including non-degenerative and
postnatal onset disorders, the current classification gives rise to confusion. Despite the discovery of new pathways
involved in PCH, treatment is still symptomatic. However, correct diagnosis of PCH is important to provide suitable care
and counseling regarding prognosis, and offer appropriate (prenatal) genetic testing to families.
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Background
Pontocerebellar Hypoplasia (PCH) was originally de-
scribed as a heterogeneous group of prenatal onset
neurodegenerative disorders, mainly but not exclu-
sively affecting cerebellum and pons. The first report
on PCH dates from 1917 [1]. Two reports that
followed used the term ‘hypoplasia ponto- neocerebel-
laris’ to indicate the relative sparing of the cerebellar
vermis compared to the cerebellar hemispheres [2, 3].
In 1928, the clinical characteristics of a patient with
PCH were for the first time described by Krause [4].
He described a 16 months old, atrophic child with
swallowing impairment, spasticity and jerky move-
ments of the limbs; in retrospect this description and
neuropathological profile fits PCH2. In 1961 the first
patient with PCH and spinal motor neurodegeneration
as seen in Werdnig-Hoffman disease (or spinal
muscular atrophy, SMA) was reported [5]. More re-
ports of similar patients followed, indicating that the
combined occurrence of PCH and bulbo-spinal motor
neuron degeneration was not an incidental finding but
a distinct syndrome [6–8]. In 1990, Barth et al. de-
scribed 7 affected children from 5 families from a
Dutch genetic isolate, with PCH, microcephaly, severe
extrapyramidal dyskinesia and absence of voluntary
movement [9]. The extrapyramidal hyperkinesia in
PCH was previously reported by Peiffer & Pfeiffer
(1977) [10]. In 1993, a first classification of PCH was
proposed that included two subtypes, PCH1 and
PCH2 [11]. PCH1 is characterized by anterior horn
degeneration in the spinal cord with muscle weakness
and hypotonia. PCH2 is distinguished by neonatal jit-
teriness, incoordination of sucking and swallowing,
lack of voluntary motor development and grasping
and – in most patients- almost complete absence of
cognitive development [11].
Since the original description of PCH, the phenotype
has been significantly broadened. Nine different subtypes
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were added to the classification of PCH, initially based
upon distinct clinical, radiological or biochemical fea-
tures (like optic atrophy, CSF lactate elevation), and later
followed by the finding of associated gene defects
(Table 1; Fig. 1). Inheritance of all PCH subtypes is auto-
somal recessive. Great clinical and neuroradiological
variability exists within and between the different sub-
types. Overall, PCH is a severe disorder with very limited
or sometimes virtually absent developmental progress,
and often early lethality. Most of the clinical neurological
findings pertain to dysfunction of the cortex and basal
ganglia, including severe intellectual disability, central
motor impairments and epilepsy. Obvious cerebellar
symptoms are very rarely reported in PCH, despite the se-
vere cerebellar involvement shown by neuroimaging. The
clinical features and genetics of the different subtypes, as
well as the differential diagnosis of PCH and possible dis-
ease mechanisms, will be discussed separately below.
Main text
PCH1
PCH1 is characterized by PCH with in addition bulbar
and spinal motor neurodegeneration identical to spinal
muscular atrophy (SMA) as seen in routinely stained
spinal cord sections. Early reports describe PCH1 as a
neonatally lethal disorder with polyhydramnios, congeni-
tal contractures, respiratory failure and severe muscle
hypotonia [6, 11]. Later studies describe sparing of the
ventral pons and survival into puberty, thereby broaden-
ing the clinical and neuroradiological spectrum of PCH1
[12, 13]. Currently, four genes are associated with PCH1
(PCH1A-D). Mutations in the vaccinia-related kinase 1
gene (VRK1, OMIM # 607596)) are a very rare cause of
PCH1; VRK1 mutations are described in one consan-
guineous PCH1 family of Ashkenazi Jewish origin [14].
The phenotype of these patients was atypical for PCH:
patients had severe microcephaly from birth on while
Fig. 1 Simplified representation of main characteristic symptoms in PCH and similar conditions. DSD=Disorder of Sex Development, CC = Corpus
callosum, MEB =Muscle-eye-brain disease, WWS=Walker Warburg syndrome, CDG1A = Congenital disorder of Glycosylation type Ia, SCA = Spinocerebellar
ataxia. Note that exceptions are possible in most categories due to large phenotypic variability. *The strongest correlation of a dragonfly configuration of
the cerebellum and dystonia is with PCH2A. In other PCH2 subtypes, that are all very rare, cerebellar hypoplasia may be less profound and extrapyramidal
movement disorders absent. In PCH2E, brain MRI is initially normal; cerebellar atrophy becomes apparent in the first year of life. In addition, osteoporosis
and scoliosis were reported in PCH2E.** (Relative) sparing of the pons can also be seen in milder affected patients with other PCH subtypes
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cognitive development seemed only mildly affected [14].
Later, VRK1 mutations turned out to be predominantly
associated with motor neuron disease without PCH
[15, 16]. Subsequent studies found pathogenic muta-
tions in EXOSC3 (OMIM # 614678) in roughly half
of the patients with PCH1 [12, 13, 17]. EXOSC3 en-
codes component 3 of the exosome complex, which is
involved in mRNA degradation. Mutations in EXOSC3
were clinically associated with prolonged survival (mean
age at death was nine months in patients with mutations
versus three months in patients without EXOSC3 muta-
tions) [13]. Respiratory failure, congenital contractures
and polyhydramnios were rarely reported in the EXOSC3
mutation group [13]. Cerebellar hypoplasia was variably
present and the pons was unaffected in a part of the
patient group, depending on the genotype (Fig. 2a-d)
[12, 13]. Mutations in EXOSC8 (OMIM # 61608), like
EXOSC3 encoding a component of the exosome com-
plex, were found to cause psychomotor retardation,
severe muscle weakness, spasticity, hearing and vision
impairment and motor neuron degeneration in 22
patients from three families. Neuroimaging showed
hypoplasia of the cerebellum and corpus callosum,
cortical atrophy and immature myelinisation [18].
Mutations in SLC25A46 (OMIM 610826) were shown
to cause lethal pontocerebellar hypoplasia [19]. Muta-
tions in this gene were also found to be the under-
lying genetic cause in the original Dutch PCH1
family, which was described by Barth to delineate the
PCH1 phenotype as a distinct subtype of PCH [20].
With the identification of SLC25A46 mutations, for
the first time a genetic basis for the most severe
spectrum of the PCH1 phenotype was revealed.
PCH2
Probably PCH2A is the most prevalent and best character-
ized of all PCH subtypes. PCH2A is caused by homozy-
gosity for a founder mutation (p.A307S) in the TSEN54
gene (OMIM # 277470), which was identified by linkage
analysis in 9 affected families from a Dutch genetic isolate
[21]. Clinically, PCH2A is distinguished by generalized
clonus and incoordination of sucking and swallowing in
Table 1 Overview of PCH subtypes with associated gene defect. DSD = Disorders of Sex Development. * Imaging suggests postnatal
onset of neurodegeneration in (a subset of) patients in this group
Subtype Symptoms/ distinctive features in addition to PCH Subcategory and
gene (#OMIMnr)
Gene function Key references
PCH1 Motor neuron degeneration, muscle weakness,
hypotonia, respiratory insufficiency, congenital
contractures
PCH1A: VRK1 (#607596) Neuronal migration [14-16]
PCH1B: EXOSC3 (#614678) mRNA degradation [12, 13, 17]
PCH1C: EXOSC8 (#616081) mRNA degradation [18]
PCH1D: SLC25A46 (*610826) Mitochondrial fission and fusion [19, 20]
PCH2 Generalized clonus, impaired swallowing,
Dystonia, chorea, progressive microcephaly
PCH2A: TSEN54 (#277470) tRNA splicing [21, 22, 24]
PCH2B: TSEN2 (#612389) tRNA splicing [21, 25]
PCH2C: TSEN34 (#612390) tRNA splicing [21]
PCH2D*: SEPSECS (#613811) Selenocysteine synthesis [27-29]
PCH2E: VPS53 (#615851) Unknown [30]
PCH2F: TSEN15 (#617026) tRNA splicing [26]
PCH3 Facial dysmorphism, optic atrophy, cerebellar
atrophy
PCLO* (#608027) Regulation synaptic protein
& vesicle formation
[31-33]
PCH4 Severe form of PCH2 with congenital contractures
and polyhydramnios
TSEN54 (#225753) tRNA splicing [21, 34]
PCH5 Severe form of PCH2 with congenital contractures
and polyhydramnios (identical to PCH4)
TSEN54 (#610204) tRNA splicing [37, 38]
PCH6 Hypotonia, seizures, elevated CSF lactate,
progressive supratentorial atrophy
RARS2* (#611523) Arginyl tRNA synthetase [39, 40]
PCH7 DSD, thin corpus callosum, enlarged ventricles TOE1 (#614969) RNA processing [52]
PCH8 Abnormal muscle tone, dystonia, ataxia, no/little
disease progression. Non-degenerative.
CHMP1A (#614961) Regulation INK4A [54]
PCH9 Abnormal muscle tone, impaired swallowing,
corpus callosum agenesis and ‘Fig. 8’ configuration
of brainstem
AMPD2 (#615809) Regulation GTP synthesis [55-58]
PCH10 Abnormal muscle tone, seizures, motor neuron
degeneration, mild cerebellar hypoplasia/atrophy
CLP1 (#615803) tRNA splicing [59-60]
PCH11 Non-progressive/ non-degenerative PCH. TBC1D23 (# 617695) Intracellular vesicle transport [61, 62]
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the neonate. The toddler and young child suffer from
spasticity, dystonia/chorea and epilepsy and show a lack of
voluntary motor development and grasping and almost
complete absence of cognitive development [21–23]. Pa-
tients often suffer from feeding problems requiring PEG
feeding. In PCH2A sleeping disorders, recurrent infec-
tions, apneas and problems in temperature regulation are
reported in the majority of patients. Microcephaly, usually
absent in the neonatal period, is progressive, and caused
by supratentorial atrophy. Mean OFD at the age of 5 years
was − 5.58 SD in a cohort of 33 patients studied by Sán-
chez and colleagues [24]. Life expectancy is reduced: more
than 50% of patients die before puberty [24]. Homozygos-
ity for the p.A307S mutation is strongly correlated with a
‘dragonfly’ configuration of the cerebellum on brain MRI,
resulting from severely affected hemispheres (‘the wings’)
and relative sparing of the vermis (‘ the body’; Fig. 2e-f)
[22]. TSEN54 is part of the transfer-RNA (tRNA) splicing
endonuclease complex: a complex involved in splicing of
intron containing pre-tRNAs. The TSEN complex consists
of four protein subunits: two catalytic (TSEN2 and
TSEN34) and two structural (TSEN15 and TSEN54) ones.
(Trotta 1997, Cell). Mutations in TSEN2, TSEN34 and
TSEN15 rarely occur, resulting in a phenotype similar to
PCH2 [22, 25, 26]. These subtypes are classified as
PCH2B, PCH2C and PCH2F, respectively (respectively
OMIM # 612389, # 612390 and # 617026) [26]. Classifica-
tion of the PCH2 subtypes was done chronologically,
based on the order of the identification of respective dis-
ease genes. PCH2D is caused by mutations in the SEP-
SECS gene (OMIM # 613811) and comprises a clinical
spectrum with variable severity and some patients lack
pontine hypoplasia [27–29]. In addition, patients with
cognitive impairment and initial normal motor develop-
ment with pediatric onset ataxia and motor decline have
been described [29]. VPS53 mutations (OMIM # 615851)
were identified in four families of Jewish Moroccan
ancestry and resulted in a PCH-like phenotype (PCH2E)
[30]. VPS53 is one of the four subunits composing the
Golgi-associated retrograde protein complex, involved in
transporting endosomes to the trans-Golgi network. In all
ten patients, pregnancy was uncomplicated and head
circumference was normal at birth. During the first
months of life, a delay in motor and cognitive develop-
ment became apparent. Progressive spasticity, spastic
quadriplegia, multiple contractures, progressive micro-
cephaly and seizures evolved during infancy. Osteoporosis
and scoliosis were reported. Initial brain imaging was
normal, but cerebellar atrophy was noted in the first year
of life followed by cerebral atrophy. All patients had pro-
found mental retardation [30].
PCH3
Pontocerebellar hypoplasia type 3, in the literature also
referred to as cerebellar atrophy and progressive micro-
cephaly (CLAM), is characterized by pontocerebellar hy-
poplasia/atrophy, thin corpus callosum, progressive
microcephaly, seizures, small stature, facial dysmorphism
and in some patients optic nerve atrophy. The extrapyr-
amidal movement disorders that are typically seen in
PCH2 are absent [31–33]. In 2015, it was shown that
mutations in the PCLO (#608027) gene underlie PCH3
in a sibship form the Sultanate of Oman [31]. In 2009, a
Turkish patient was described with a highly similar
phenotype to the Omani patients [33]. The locus was
mapped to the same region on chromosome 7q, in the
region where the PCLO gene is located, but it remains
unknown whether aberrations in this gene underlie the
phenotype in this patient as well.
PCH4&5
Pontocerebellar hypoplasia type 4, previously reported in
the literature as olivopontocerebellar hypoplasia due to in-
volvement of the inferior olivary nuclei, is at the severe
(See figure on previous page.)
Fig. 2 MR images in different PCH subtypes. a-b. Coronal (a) and midsagittal (b) image of severely affected PCH1B patient (age 3 weeks,
homozygous for the p. G31A mutation in EXOSC3), showing severe hypoplasia of cerebellar hemisphere with relative sparing of the vermis
(indicated by arrowhead). The ventral pons is reduced in size but not completely flattened (indicated by arrow). c-d. Coronal (c) and midsagittal
(d) image of PCH1B patient (age 2,5 months) with milder EXOSC3 mutations(the patient is homozygous for the p.D132A mutation). Cerebellar
hypoplasia is very mild, with bilateral hyperintensities in the hili of the dentate nucleus. Size and shape of the ventral pons are normal. e-f.
Coronal (e) and midsagittal (f) image of PCH2A patient (age 7 days, homozygous for the TSEN54, p.A307S mutation) with severe flattening of
cerebellar hemispheres with relative sparing of the vermis (indicated by arrowhead) resulting in the ‘dragonfly’ configuration typical of PCH2A.
This pattern is also seen in some PCH1 patients, as shown in 1A. The ventral pons is reduced in size but not completely flattened. g-h. Coronal
(g) and midsagittal (h) image of PCH4 patient (age 6 weeks, compound heterozygous for the p. A307S mutation and a frameshift mutation in the
TSEN54 gene). Note severe flattening of pons and severe hypoplasia of the cerebellum without sparing of the vermis and profound supratentorial
atrophy (indicated by asterisks). i-j. Coronal (i) and midsagittal (j) image of a PCH6 patient (age 6 months, compound heterozygous for mutations
in the RARS2 gene) with strikingly rapid progression of supratentorial atrophy (indicated by asterisks) and relatively slight atrophy of cerebellar
hemispheres with normal pons and brainstem. k-l. Coronal (k) and midsagittal (l) image of a PCH7 patient (age 8 months, with biallelic mutations
in the TOE1 gene), showing severe pontocerebellar hypoplasia, equally affecting hemispheres and vermis. Note very thin corpus callosum and
profound ventriculomegaly (indicated by asterisks and ^, respectively). m-n. Coronal and midsagittal image of a PCH9 patient (age 2 years,
homozygous for a mutation in the AMPD2 gene), showing characteristic ‘figure 8’ shaped brainstem and corpus callosum agenesis (indicated by a
circle and arrowhead, respectively).o-p. Coronal and midsagittal image of a control
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end of TSEN54-related PCH spectrum. Clinically, PCH4
presents as a severe form of PCH2, with prenatal onset of
symptoms including polyhydramnios and congenital con-
tractures, prolonged neonatal clonus, hypertonia and pri-
mary hypoventilation requiring prolonged mechanical
ventilation. Survival beyond the neonatal period is rare
[22]. Neuropathology in PCH4 shows delayed maturation
and reduced growth of the cerebral cortex. Pericerebral
fluid accumulation is regularly seen, and probably results
from shrinkage of the brain due to severe atrophy [22].
Extensive gliosis and a decreased number of neurons in
the thalamus and caudate nucleus have been reported
[34]. The cerebellar hemispheres were severely hypoplastic
and devoid of Purkinje cells, while at most only remnants
of the dentate nucleus could be identified [35, 36]. Hypo-
plasia of the cerebellar vermis is variable; but overall the
vermis is more severely affected than in PCH2 (Fig. 2g-h)
[22]. An important neuropathological difference with
PCH2 is the lack of folding of the inferior olivary nuclei,
resulting in a horseshoe shape [35]. The more severe clin-
ical course in PCH4 is reflected by the type of mutation in
TSEN54. In PCH2A, patients are homozygous for the
p.A307S missense mutation. In PCH4, patients are com-
pound heterozygous with on one allele this hypomorphic
missense mutation and a premature stop- or splice site
(loss-of-function) mutation on the other allele. The latter
combination of mutations is more detrimental for protein
function and results in a more severe phenotype of PCH4
compared to PCH2. The distinction between PCH4 and
PCH5 was initially based upon the presence of prenatal
seizures and a more severely affected vermis compared to
the hemispheres in a single PCH5 family [37]. However,
Namavar et al. showed that, as in PCH4, compound het-
erozygous TSEN54 mutations, one being hypomorphic
and the other being a loss-of-function mutation, underlie
PCH5. The distinction of PCH5 as a separate subtype is
therefore redundant [38].
PCH6
The canonical PCH6 phenotype consists of severe early
onset epilepsy, progressive global atrophy including pons
and cerebellum, lactic acidosis and/or mitochondrial re-
spiratory chain defects [39]. PCH6 is caused by muta-
tions in the nuclear encoded mitochondrial Arginine
tRNA-synthetase (RARS2), which is responsible for cata-
lyzing the specific attachment of Arginine to its cognate
mitochondrial tRNA [40]. Currently, 31 patients with
RARS2 mutations (OMIM # 611523) have been reported
[39–49]. None of them have biallelic null mutations, im-
plicating that complete abolishment of mitochondrial
tRNA-arg would be lethal. Splice site, nonsense or mis-
sense mutations are identified throughout the RARS2
gene, while no clear genotype-phenotype correlation
could be established [49]. All patients surviving the
neonatal period had severe developmental delay, and al-
most all suffered from refractory epilepsy. The majority
of patients had elevated lactic acid in plasma or CSF. Re-
spiratory chain deficiency in fibroblasts or muscle could
not be confirmed in all these patients. Brain MRI
showed cerebellar hypoplasia/atrophy of variable sever-
ity. Some early MRIs were normal or showed mild ver-
mal hypoplasia, with often rapidly progressive atrophy of
supra- and infratentorial structures (Fig. 2i-j) [49].
PCH7
PCH7 is characterized by the rare combination of PCH
with disorders of sex development (DSD). Patients show a
severe developmental delay, profound truncal hypotonia
with hypertonic limbs and brisk deep tendon reflexes, and
seizures. Disorders of sex development were most appar-
ent in 46, XY patients, who showed undervirilisation ran-
ging from almost completely differentiated female
external genitalia to micropenis with hypoplastic scrotum.
In some XY patients, uterine or ovarian remnants could
be found, while others had atrophic testes or no gonadal
tissue at all [50–53]. Clinical information on XX patients
was provided for three affected individuals. Two had nor-
mal external female genitals, and one patient had a prom-
inent clitoris. In one patient the ovaries could not be
detected by ultrasound, while the uterus was present [52].
Patients of both sexes manifest profound hypoplasia of
pons and cerebellum, a thin corpus callosum and enlarged
ventricles with irregular borders as a consequence of re-
duced cerebral white matter (Fig. 2k-l) [51, 52]. Only one
neuropathological report is available, provided by Ander-
son in 2011, which showed cerebral atrophy with a pro-
found reduction in white matter. The cerebellar
hemispheres were almost absent; only rudimentary folia
devoid of neurons could be identified. The vermis was
relatively spared. The ventral pons lacked pontine nuclei,
while the pontine tegmentum was relatively normal. The
inferior olivary nuclei could not be identified [51]. In
2017, biallelic mutations in TOE1 (OMIM # 614969) were
reported in 12 families with PCH7 [52].
PCH8
Only three families with PCH8 have been reported. Pa-
tients have microcephaly, a severe developmental delay
(although some patients were able to walk independently),
dystonic posturing and/or choreiform movements. Some
patients had (congenital) contractures and seizures. In
contrast with the other PCH subtypes, PCH8 seems to be
a stable neurologic condition without clear evidence of
disease progression. Brain imaging showed profound pon-
tocerebellar hypoplasia, a thin but fully formed corpus cal-
losum and a decrease in cerebral white matter in all
patients. In patients who had multiple brain MRIs, no
clear signs of ongoing neurodegeneration were noted [54].
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PCH8 might be considered as a ‘non-degenerative’ form
of PCH and is caused by mutations in the CHMP1A gene
(OMIM # 614961). CHMP1A is involved in chromatin
modelling and cell proliferation [54].
PCH9
PCH9 is characterized by progressive microcephaly, pro-
found neurodevelopmental delay, cortical visual impair-
ment, impaired swallowing, spasticity with neonatal
clonus, brisk deep tendon reflexes and truncal hypo-
tonia. Facial dysmorphisms are reported with dental ab-
normalities in a minority of patients. The presence of
axonal neuropathy is reported in older patients and is
probably age-dependent [55–57]. Brain MRI showed
pontocerebellar hypoplasia, severe hypoplasia of the cor-
pus callosum with, on axial images, a characteristic ‘fig-
ure 8’ shape of the mesencephalon, with hypoplastic
cerebral peduncles (Fig. 2m-n) [55–58]. PCH9 is caused
by mutations in the AMPD2 gene (OMIM # 615809),
which encodes one of the three adenosine monopho-
sphate deaminases. Interestingly, mutations in the same
gene have also been associated with spastic paraplegia
63 (SPG63; OMIM #615686).
PCH10
Nine families of Turkish origin have been reported with
PCH10 [59, 60].Mutations in CLP1 has been identified
as the causal gene defect (OMIM # 615803). CLP1 inter-
acts with the TSEN complex and is also involved in
tRNA splicing (see below). Clinical characteristics are a
severe developmental delay, seizures, progressive spasti-
city, facial dysmorphism, microcephaly and signs of
axonal neuropathy of both motor and sensory neurons.
Brain MRI showed a thin corpus callosum, delay in mye-
linisation and hypoplasia of the ventral pons/thinning of
the brainstem. Atrophy of the cerebellum is, if present at
all, very mild compared to the other subtypes of PCH.
PCH11
Seven families with PCH11 have been reported. Patients
were homozygous for truncating or splice site mutations
in the TBC1D23 gene (OMIM # 617695) [61, 62].
PCH11 is characterized as another non-degenerative
form of PCH and is characterized by a severe neurode-
velopmental delay, microcephaly and hypotonia. Seizures
were reported in 2/13 patients. Some patients were able
to walk alone. Specific cerebellar symptoms like ataxia
were reported in roughly half of the patients; this implies
that some degree of voluntary movement was present in
those patients. Brain MRI showed non-progressive hypo-
plasia of pons and cerebellum with hypoplasia of the
corpus collosum [61, 62].
Management and treatment
No curative treatment is available for any type of PCH.
Treatment is symptomatic in all subtypes. PCH2A is the
most prevalent subtype of PCH, and the only type in
which adequate patient numbers allowed a systematic
study of its clinical course. PCH2A patients often suffer
from feeding problems starting immediately after birth
requiring gavage or PEG feeding. Sleep apnoea, which is
a frequently reported and life-threatening complication
in PCH, and which may lead to sudden infant death, can
be detected by sleep monitoring [24]. Seizures in
PCH2A are difficult to treat, but a relatively good effect
on phenobarbital and topiramate is reported (resulting
in a reduction in seizure frequency in 11 out of 15 and 6
out of 7 patients, respectively) [24]. Choreathetoid move-
ments are present in about 90% of patients. [22, 24]
Opisthotonic posturing can be prevented by flexure of the
large joints. An ergonomically shaped wheelchair and
physiotherapy can be beneficial in achieving this. In one
PCH2 patient, an improvement of dystonic crises and
choreoathetosis upon treatment with Levodopa was re-
ported [63]. Rhabdomyolysis and strongly elevated serum
creatine kinase have been repeatedly reported and should
be carefully monitored, especially during episodes of infec-
tion [23, 64–66]. Muscle biopsies and serum CK measure-
ments of some PCH2 patients without any muscular
symptoms showed evidence for a subclinical myopathy in
a part of the PCH2 population [65].
PCH9 has been considered to be a potentially treatable
disorder, because administration of a purine nucleotide
precursor (AICAr) could rescue the phenotype at a cel-
lular level. Follow-up experiments are needed, because it
was shown that administering of AICAr tends to inhibit
axonal growth in mouse cultures neurons [55].
Differential diagnosis of pontocerebellar hypoplasia/atrophy
Cerebellar hypoplasia and cerebellar atrophy are both
relatively common and nonspecific findings occurring in
a very heterogeneous group of disorders [67]. Hypoplasia
refers to a static condition in which the cerebellum has a
normal shape but is too small, while atrophy refers to
progressive loss of cerebellar tissue, resulting in progres-
sive widening of interfolial spaces. The distinction be-
tween hypoplasia and atrophy may be easy to make on
theoretical grounds; in practice however this can be
challenging or even impracticable when based on a sin-
gle brain imaging study.
Neuropathology reports in PCH2A mention both hypo-
plastic features with shortening of cerebellar folia with re-
duced branching (‘stunted folial growth’) and degenerative
changes like thinning of the cerebellar cortex [35]. A mech-
anism of prenatal onset neurodegeneration is assumed,
which is reflected by the ongoing postnatal neurodegenera-
tion of the cerebral cortex, resulting in progressive
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microcephaly and widening of the lateral ventricles. The
use of the term ‘hypoplasia’ in PCH is explained by historic
reasons: at the time of the first descriptions of PCH, the
concept of prenatal onset neurodegenerative disorders was
yet unknown. Therefore, it was common to describe this
congenital defect as ‘hypoplasia’.
Many metabolic disorders and genetic syndromes dis-
play cerebellar hypoplasia/atrophy. Careful assessment
of the neuroimaging pattern is essential to evaluation. In
PCH vermal growth is relatively spared compared to the
cerebellar hemispheres, while in disorders like Joubert
syndrome and Dandy-Walker malformation the vermis
is mainly affected. The molar tooth sign, caused by
elongation and a more horizontal course of the superior
cerebellar peduncle, is characteristic of Joubert
syndrome. While cerebellar hypoplasia has a broad dif-
ferential diagnosis, the presence of pontine hypoplasia
significantly narrows down the diagnostic options. Pon-
tine hypoplasia affects the basis of the pons, and is
mainly due to loss of ventral pontine neurons and trans-
verse pontine fibers. However, the combination of pon-
tine and cerebellar hypoplasia, does not automatically
result in a diagnosis of PCH as discussed here. The use
of the term ‘PCH’ is not uniform which may give rise to
confusion. Some of the disorders that share pontine and
cerebellar hypoplasia as a feature on MRI are discussed
below (and Table 2).
Congenital disorder of glycosylation type 1A (CDG1A)
Congenital disorders of Glycosylation type 1a (CDG1a;
OMIM #212065) present with global (ponto)cerebellar
hypoplasia with superimposed atrophy on brain MRI
[68, 67]. In addition to PCH, supratentorial atrophy with
enlarged ventricles and delayed myelinisation can be
present. [67, 68] Clinical presentation of CDG1a is
highly variable: ranging from severe neonatal onset
multi-organ failure to a stable neurological condition
with moderate mental retardation and ataxia. Typical
dysmorphic features are inverted nipples and abnormal
fat distribution [69–71]. CDG1a is caused by autosomal
recessive mutations in the PMM2 gene and can be ex-
cluded by isoelectric focusing of transferrines. Cerebellar
involvement is also reported in several other (rare) forms
of CDG [72].
Pontocerebellar hypoplasia with neocortical malformations
CASK – related disorders Loss of function mutations
and (partial) deletions of the CASK gene, which is located
on the X chromosome, are associated with microcephaly
with pontine and cerebellar hypoplasia (MICPCH, OMIM
# 300749) [73]. Pons and cerebellum can be severely hypo-
plastic, resembling PCH. Neocortical dysgenesis and
malformations can be present in addition (e.g. reduction of
number and complexity of frontal gyri and blurring of
neocortical grey-white matter border) [73, 74].
Loss-of-function mutations and deletion often occur de
novo. CASK- related PCH is clinically highly variable but is
distinguished form PCH1 and PCH2 by the absence of
motor neuron degeneration and chorea, respectively. CASK
Patients show additional features like minor facial dys-
morphisms (e.g. a round face with small chin, large nasal
bridge), sensorineural hearing loss and ophthalmologic ab-
normalities [75]. The degree of cerebellar hypoplasia is vari-
able, while the cerebellar hemispheres and vermis are
equally involved without sparing of the vermis as seen in
PCH1 and PCH2. The cerebellar hemispheres show asym-
metry in some patients. Although developmental delay is
severe, some patients achieve milestones like independent
sitting or walking and speaking few single words [75].
Genes involved in the organization of microtubuli
Microtubuli play a key role in development of the brain
by providing mechanical forces needed for cell division,
axon guidance and neuronal migration [76, 77]. Muta-
tions in several genes involved in tubulin formation are
associated with a range of cortical malformations includ-
ing lissencephaly and polymicrogyria, often combined
with variable degrees of cerebellar hypoplasia and brain
stem malformations [77]. TUBA1A mutations (OMIM #
611603) account for about 30% of patients with lissence-
phaly and cerebellar hypoplasia [78]. Other genes in the
tubulin pathway that are associated with similar neuro-
radiological features are: TUBB2B, TUBB3, TUBB5 and
TUBA8 [77].
RELN and VLDLR mutations Autosomal recessive
mutations in RELN (OMIM* 600514) result in lissence-
phaly with severe pontocerebellar hypoplasia and abnor-
mal hippocampus [77, 79]. In contrast to PCH2, the
cerebellar vermis is also very hypoplastic and often com-
pletely lacks foliation [78]. The Reelin signaling pathway
is important for neuronal migration during development
[77, 79]. The very low density lipid receptor (encoded by
the VLDLR gene, OMIM# 224050) is an important
player in this pathway and aberrations of VLDLR result
in a similar, although generally milder, neurodevelop-
mental phenotype. Cortical malformations are milder,
cerebellar ataxia is non-progressive and some patients
have been described with a characteristic quadrupedal
gait [80, 81].
α- dystroglycan related dystrophies Defects in O-man-
nosyl-linked-glycosylation of α- dystroglycan underlie this
group of heterogeneous congenital muscular dystrophies.
The associated phenotypes form a wide clinical spectrum
and are roughly divided in three main groups, depending
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on clinical severity: Fukuyama congenital muscular
dystrophy, muscle-eye-brain disease and Walker-Warburg
syndrome (WWS). Main characteristics are muscle
weakness with increased serum CK, delayed motor
development and severe cognitive impairment and
opthalmological abnormalities (e.g. optic nerve atrophy,
congenital glaucoma). Brain malformations include
dysplastic supratentorial malformations (e.g. cobblestone
lissencephaly or polymicrogyria) and cerebellar and pontine
hypoplasia [82]. Also patients with a normal appearing
brain MRI are reported [83]. Isolated cerebellar
involvement occurs rarely [84].
X-linked Hoyeraal-Hreidarsson syndrome
X-linked Hoyeraal-Hreidarsson syndrome (XL-HHS) is
characterized by intrauterine growth retardation, micro-
cephaly, failure to thrive, developmental delay combined
with progressive bone marrow failure, aplastic anemia and
combined immunodeficiency [85, 86]. Neuroradiologic
features are (ponto)cerebellar hypoplasia, hypoplastic cor-
pus callosum, delayed myelination, focal high intensities
in the brainstem and thalamus, and subcortical
calcifications [87]. XL-HHS is caused by mutations in the
DKC1 gene (OMIM # 305000). DKC1 is also involved in
dyskeratosis congenital (DC), a syndrome characterized
Table 2 Differential diagnosis of Pontocerebellar Hypoplasia (PCH)
Disease Distinctive features Gene(s) involved references
Congenital disorder of
Glycosylation Ia (CDGIa)
Clinical: neonatal onset multi organ failure,
dysmorphic features, ataxia. Microcephaly.
MRI: global PCH with superimposed atrophy,
supratentorial atrophy, ventriculomegaly,
delayed myelinisation.
PMM2 [68, 69, 72]
CASK- related disorders Clinical: facial dysmorphism, sensorineural
hearing loss, ophthalmologic abnormalities.
Developmental progress in a subgroup of
patients. No MND or chorea. Progressive
microcephaly.
MRI: variable degree of PCH, equally affecting
hemispheres and vermis. Cortical malformations
can be present.
CASK [73-76]
Tubulin defects Clinical: DD, seizures. Progressive microcephaly.
Optic atrophy in some cases.
MRI: cortical malformations (eg lissencephaly,
polymicrogyria) with cerebellar hypoplasia and
brainstem malformations.
TUBA1A, TUBB2B, TUBB3, TUBB5, TUBA8 [77-79]
RELN & VLDLR mutations Clinical: Severe DD, hypotonia, epilepsy,
nystagmus. In VLDLR: non-progressive ataxia,
quadrupedal gait.
MRI: lissencephaly, severe PCH and abnormal
hippocampus, milder in VLDLR.
RELN, VLDLR [80-82]
α- dystroglycan related dystrophies
(WWS, MEB, Fukuyama congenital
muscular dystrophy)
Clinical: severe DD, muscle weakness with
increased CK, ophthalmologic abnormalities.
WWS at the severest end of the spectrum.
MRI: wide spectrum of brain malformations
including cobblestone lissencephaly, PCH,
congenital hydrocephalus.
POMT1, POMT2, POMGnT1, LARGE, FKTN,




Clinical: IUGR, microcephaly, failure to thrive,
progressive bone marrow failure, aplastic
anemia, combined immunodeficiency, some
symptoms of DC.
MRI: PCH, delayed myelinisation, focal high





Clinical: Ataxia, developmental progress, some
cases with retinitis pigmentosa or cone-rod
dystrophy.
MRI: (ponto) cerebellar hypoplasia/atrophy,
no supratentorial atrophy.
ITPR1, ATXN7, ATXN2 [88-92]
Extreme prematurity (< 32 weeks) Clinical: motor and cognitive impairment
of variable degree, autism spectrum disorders
MRI: PCH, signs of cerebellar or cerebral injury,
eg hemorrhage. Non progressive.
n/a [95-97]
MND motor neuron degeneration, DD developmental delay, CK creatine kinase, WWS Walker-Warburg syndrome, MEB Musce Eye Brain disease, IUGR Intrauterine
Growth Retardation, DC dyskeratosis congenita
van Dijk et al. Orphanet Journal of Rare Diseases  (2018) 13:92 Page 9 of 16
by bone marrow failure and a characteristic triad of abnor-
mal skin pigmentation, oral leucoplakia and nail dystrophy
[85, 86]. In XL-HHS, these characteristic mucocutaneous
features of DC can be present [85, 87].
Spinocerebellar ataxias
Hypoplasia and/or atrophy of the cerebellum at early
age can manifest in pediatric onset types of spinocere-
bellar ataxia (SCA). The SCA’s refer to a heterogeneous
group of autosomal dominant inherited ataxia’s of vary-
ing severity and age of onset [88]. Brainstem involve-
ment is not a regular finding in SCA, but has been
reported in later disease stages of very severe infantile
onset SCA2 and SCA7 [89–91]. Usually other findings
like retinitis pigmentosa or cone-rod dystrophy are
present in SCA2 and SCA7, that distinguish these condi-
tions from PCH. More recently, it has been shown that
mutations in ITPR1, can result in severe pontocerebellar
hypoplasia, mimicking PCH [93]. Supratentorial atrophy
was absent in this patient, while she clearly showed de-
velopmental progress.
ATADA3 deletions/mutations
Biallelic deletions of the ATAD3A gene are associated
with a lethal prenatal onset disorder characterized by
polyhydramnios, contractures, severe pontocerebellar
hypoplasia, microcephaly, abnormal basal ganglia and
abnormalities of cortical gyration [94]. The ATAD3 gene
cluster comprises three genes that are arranged in tan-
dem: ATAD3C, ATAD3B and ATAD3A [94]. Both homo-
zygous deletions affecting the ATAD3A/ ATAD3B genes
as well as some combinations of a null allele with mis-
sense mutations in ATAD3A are associated with this le-
thal phenotype. Milder mutations in ATAD3A and
deletions involving ATAD3B/ATAD3C genes appear to
be associated with a milder clinical course [94, 95]. The
ATAD3 gene cluster is involved in mtDNA organization
and cholesterol metabolism [95].
Extreme prematurity
Extreme prematurity (gestational age < 32 weeks) is asso-
ciated with an increased risk of cerebellar hypoplasia of
various degrees. In severely affected patients, neurora-
diologic imaging can mimic PCH [96]. The extremely
rapid growth of the cerebellum in the third trimester re-
sults in an increased vulnerability of the premature cere-
bellum. Several (combined) mechanisms of preterm
cerebellar injury are suggested, roughly consisting of is-
chemic of hemorrhagic destructive cerebellar lesions and
cerebellar underdevelopment. In addition, effects of
supratentorial injury on the development of cerebellum
and brainstem trough involvement of cortico-cerebellar
connections have been suggested [97, 98].
Brossard-Racine et al. reviewed the clinical outcome in
preterm infants. Both motor and cognitive impairment are
significantly associated with direct cerebellar injury. Also
autistic features are often reported, especially when the
cerebellar vermis is involved. The effects of indirect cere-
bellar injury (e.g. cerebellar underdevelopment associated
with cerebral injury) on long-term development are less
well studied and studies often show conflicting results [98].
Pathomechanisms of PCH
PCH related to defects in tRNA splicing
Homozygosity for the p.A307S mutation in TSEN54 is the
most prevalent cause of PCH. As discussed above, TSEN54
is one of the four subunits of the transfer-RNA splicing
endonuclease complex (TSEN-complex). Mutations in
TSEN2, TSEN34 and TSEN15 occur very rarely. The TSEN
complex is involved in the cleavage of intron containing
tRNAs (Fig. 3a). tRNAs contain an anticodon sequence by
which they recognize the codon of the mRNA template
that is being translated. By transferring the required amino
acid to the ribosomal complex for incorporation in the pep-
tide chain, tRNAs are essential for protein translation. The
human genome contains 506 genes that encode tRNAs;
providing templates for multiple tRNAs for each codon.
Only a minority of these tRNA genes (6%) contains an in-
tron. For some amino acids however, the vast majority of
tRNAs is intron containing (e.g. tRNA-Tyr (GTA) and
tRNA-Ile (TAT)) (http://gtrnadb.ucsc.edu/). It is hypothe-
sized that TSEN-complex defects result in impaired tRNA
splicing and subsequently a decrease in protein transla-
tion. However, results of in vitro experiments studying
the effect of the A307S mutation on tRNA splicing are
ambiguous. Budde et al. reported no unspliced
tRNA-Tyr products in patient fibroblasts, measured by
RNA blot analysis [21].
CLP1, involved in PCH10, phosphorylates the 5′ ends
of 3’ tRNA halves after splicing by the TSEN complex,
thereby preparing re-ligation of the spliced tRNA halves
by an unknown ligase. CLP1 is also known to interact
with the TSEN complex; an interaction required for effi-
cient tRNA splicing. It was shown that the R140H muta-
tion in CLP1 hampers interaction with the TSEN
complex, and thereby impairs tRNA splicing in vitro. In
patient derived iNeurons, an accumulation of some
pre-tRNAs with a corresponding reduction in mature
tRNAs was found [59, 60].
PCH related to other defects in RNA processing and protein
translation
Two subunits of the RNA exosome complex are in-
volved in PCH. EXOSC3 functions as a RNA binding
unit and is located in the cap of the complex, while
EXOSC8 is one of the six subunits that composes the
core ring. The exosome complex is important for
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degradation of mRNA and ribosomal RNA (rRNA) frag-
ments and for maturation of certain rRNAs (Fig. 3b and
see Fasken et al. for comprehensive summary) [99]. A
role in tRNA degradation in human has been implied
based on roles of the exosome complex in tRNA metab-
olism in yeast [100, 101]. Modeling of human EXOSC3
mutations in S. cerevisiae affected pre-rRNA processing
[102]. Why defects in rRNA processing specifically af-
fects neurons remains unknown.
SEPSECS, mutated in PCH2D, encodes the
O-phosphoseryl-tRNA(Sec) selenium transferase enzyme,
which is needed for the final step in the synthesis of
selenocystein. Selenocystein is essential for the synthesis of
selenoproteins, but lacks its own tRNA-synthetase [27–29].
Therefore, to synthesize selenocystein, a Serine is
transferred to a tRNA sec and is then via several
steps converted to a Sec-tRNA-Sec complex (Fig. 3c)
[103]. PCH6 is caused by mutations in the nuclear
encoded mitochondrial Arginine tRNA-synthetase
(RARS2), which is responsible for catalyzing the specific
attachment of Arginine to its cognate mitochondrial
tRNA (Fig. 3c) [40]. In patient fibroblast, a reduction in
the amount of mitochondrial tRNA-arg was found, but
almost all molecules were charged. Authors suggest in-
stability of the uncharged product to explain for this [40].
TOE1, mutated in PCH7, localizes to and is important
for Cajal body maintenance, and a role of TOE1 in
splicing of pre-mRNA was suggested [104]. Recent stud-
ies provide evidence for a role of TOE1 in the matur-
ation of small nuclear RNAs and show accumulation of
incompletely processed snRNAs in patient fibroblasts
[52]. However, it remains unknown why defects in
TOE1 specifically affect brain and gonadal development.
Other mechanisms in PCH
In some of the other PCH subtypes however, the link with
RNA metabolism or protein translation is less clear. For
example, SLC25A46 (PCH1D) has a role in balancing
mitochondrial fission and fusion and maintenance of
mitochondrial cristae. Phenotypes associated with
SLC25A46- mutations range from optic nerve atrophy and
cerebellar atrophy to lethal PCH at the most severe end of
the spectrum. Vaccinia related kinase1, encoded by VRK1
and mutated in PCH1A, is implied in several fundamental
cellular processes as coordination of cell division and
regulation of Cajal body assembly [105, 106]. Knockdown
of VRK1 in a mouse model resulted in impaired neuronal
migration in the cortex and influenced the neuronal pro-
genitor cell cycle [107]. VPS53, involved in PCH2E, is one
of the four subunits composing the Golgi-associated retro-
grade protein (GARP) complex. This complex is involved
in retrograde transport to the trans-Golgi network [30].
PCLO, involved in PCH3, encodes piccolo, a presynaptic
vesicle protein with a role in synaptic vesicle organization.
a
b c
Fig. 3 Schematic representation of main pathways involved in PCH. A. Schematic and simplified representation of tRNA splicing by the TSEN
complex and CLP1. B. Schematic figure of the exosome complex including EXOSC3, located in the RNA binding cap, and EXOSC8, located in the
core ring. The exosome complex processes mRNA, rRNA and presumably tRNA. C. Upper: charging of tRNA-Arg by RARS2. Lower: conversion of
Sec-tRNA-Ser to Sec-tRNA-Sec by SEPSECS
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In addition, a role in regulating presynaptic ubiquitination
and proteostasis has been reported [108]. Piccolo was
shown to be essential for the maintenance of synaptic in-
tegrity and loss of piccolo leads to degradation of multiple
synaptic proteins and eventually to the disassembling of
the synapse [109]. It was therefore suggested that the de-
generation of synapses due to absence of piccolo might
trigger an apoptotic signal in neurons in PCH3 patients
[31]. CHMP1A (PCH8) has a function in chromatin mod-
elling and cell proliferation. It is assumed that CHMP1A,
via interaction with BMI1, has a role in inhibition of
INK4, which is a negative regulator of stem cell prolifera-
tion [54]. PCH9 is caused by mutations in the AMPD2
gene, which encodes one of the three adenosine mono-
phosphate deaminases. AMPD2 converts AMP to IMP,
which is then further processed to form guanine nucleo-
tides. It was shown that defects in AMPD2 result in a de-
pletion of guanine nucleotides and an accumulation of
specific adenosine nucleotides [55]. This accumulation
inhibited de novo purine synthesis by a negative feedback
mechanism. Of the three AMPD paralogs, AMPD2 is pre-
dominantly expressed in the cerebellum, which possibly
explains why cerebellar structures are most severely af-
fected in PCH9 [55]. PCH11 is caused by truncating and
splice site mutations in TBC1D23 gene. TBC1D23 is in-
volved in regulation of trans-Golgi membrane trafficking
[61]. Intracellular vesicle transport was shown to be af-
fected in patients fibroblasts and down regulation of
TBC1D23 in mice resulted in abnormal neural positioning
in the cortex [62].
Alteration of RNA metabolism/ protein translation is a
common mechanism behind at least some of the PCH sub-
types. However, it remains unknown why the cerebellum is
specifically affected by these defects in processes that seem
vital to other organs as well. The third trimester is a period
of tremendous growth for the developing cerebellum. It is
hypothesized that the cerebellum is extremely vulnerable to
alterations in RNA and/or protein metabolism in this spe-
cific time-window [23, 110]. This might partly explain for
the cerebellum-specific involvement.
Incidence of PCH
PCH is a very rare disorder. The exact incidence of PCH
is unknown. PCH2A caused by homozygosity for the
p.A307S mutation in TSEN54 is the most frequent type
of PCH (Fig. 4). The estimated incidence of PCH2A
is < 1:200.000 [24]. We identified mutations in PCH
related genes in 42 patients in routine diagnostic care
between 2012 and 2017. Twenty out of those 42 pa-
tients were homozygous for the p.A307S mutation, 13
patients had mutations in EXOSC3, four patients har-
boured mutations in RARS2, one patient had SEP-
SECS mutations and one had mutations in AMPD2.
We also identified hetero- or hemizygous CASK
mutations in nine patients, indicating that this is a
frequent cause of a condition similar to PCH.
Genetic counselling and prenatal testing
Counselling regarding recurrence risk should be pro-
vided and reproductive options discussed. Preconception
carrier screening is offered for PCH2A in a closed com-
munity in the Netherlands [111]. Since 2010, seven car-
rier couples were identified in this community. In
families were the causal genetic defect is identified, pre-
implantation genetic diagnosis (PGD) or invasive pre-
natal testing should be offered for family planning.
Prenatal detection of PCH by ultrasound is unreliable,
since it often fails to detect cerebellar abnormalities at
time of the routine 20 weeks screening for structural ab-
normalities [111–113].
Discussion & Conclusion
Due to development and appliance of next generation
sequencing techniques, many new PCH related genes
and phenotypes have been described. However, there are
still many patients with a clinical diagnosis of PCH, in
whom no mutations in any of the known PCH related
genes is identified.The current classification of PCH
comprises a heterogeneous group of disorders, ranging
from lethal conditions with prenatal onset as PCH1D
and PCH4 to milder forms where disease progression is
less devastating allowing survival into adolescence as
(some subtypes of ) PCH1B and PCH2D. Unfortunately,
by including such a broad range of phenotypes, the
current classification undermines two important aspects
of the original description of PCH. Both nondegenerative
conditions (e.g. PCH8 and PCH11) and disorders with a
postnatal onset (e.g. PCH2D, PCH2E and PCH10) are
included in the PCH classification, essentially ignoring
the fact that PCH was originally defined as a disorder of
prenatal onset neurodegeneration. PCH2D and PCH2E
were initially described by the authors as progressive
cerebellocerebral atrophy (PCCA and PCCA2,
Fig. 4 Pie-chart showing proportions of PCH patients per PCH
pathway. Patient numbers are estimated based on published reports
and reviews and depicted between brackets
van Dijk et al. Orphanet Journal of Rare Diseases  (2018) 13:92 Page 12 of 16
respectively), but eventually ended up as subtypes of
PCH. PCH3 was originally referred to as cerebellar atro-
phy and progressive microcephaly (CLAM), because
neuroimaging resembled cerebellar atrophy rather than
hypoplasia. The patient numbers reported in PCH 3–11
are small (with only PCH6 due to RARS2 mutations oc-
curring relatively common), therefore the full clinical
and radiological spectrum of these disorders is not com-
pletely revealed yet. The current classification of PCH is
prone to lead to confusion, because at this point it is un-
clear which disorders should be classified as PCH and
which should not.
Genotype-phenotype correlations are most clear in
TSEN54 (PCH2A and PCH4). Homozygosity for the p.
A307S mutation in TSEN54 is strongly associated with a
dragonfly configuration of the cerebellum, impaired
swallowing and extrapyramidal movement disorders in
infancy. In infants presenting with these symptoms and
neuroradiological profile, prompt testing for this specific
mutation is required. Patients compound heterozygous
for the A307S mutation with a splice site or nonsense
mutation on the other TSEN54 allele have a more severe
phenotype characterized by congenital contractures and
primary hypoventilation. In the majority of PCH pa-
tients, especially the milder ones and ones presenting
with profound cerebral degeneration or other brain mal-
formations, the diagnosis is less straightforward. Clinical,
neuroradiological, metabolic and genetic data should be
carefully evaluated and interpreted to get the correct
diagnoses. It should not be overlooked that mutations in
PCH related genes can also lead to milder phenotypes
and might be revealed in adolescents or even young
adults [114, 115]. When interpreting possible disease
causing variants identified with whole exome sequen-
cing, Genematcher can be a very useful tool to identify
similar patients. Genematcher is an online tool where
clinicians or researchers can enter their gene of interest
and will be connected to others with an interest in the
same gene [116]. Targeted gene panels have been devel-
oped to facilitate fast genetic diagnosis in PCH, but run
the risk of being outdated soon because of the acceler-
ated rate of new gene discovery.
The identification of novel genes resulted in new insights
regarding the disease mechanism. Besides defects in RNA
metabolism and protein synthesis, also other mechanisms
like mitochondrial dysfunction (SLC25A46) and chromatin
modelling (CHMP1A) are implied in PCH. Despite the dis-
covery of new pathways involved in PCH, treatment is still
symptomatic. PCH is a very rare disorder; in some subtypes
only a few families are described. In addition, although clin-
ical course is variable, the brain structure is already severely
affect at birth in most children. These factors, together with
the heterogeneous etiology in PCH, complicate the devel-
opment of a targeted therapeutic strategy.
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